Introduction: Few studies have described the prevalence and lung function decline 48 among those with restrictive spirometric pattern (RSP) in low-and middle-income 49 countries.
INTRODUCTION 66
Chronic respiratory disease affects 1 billion people globally and accounts for 7% of all 67 deaths worldwide 1 . The majority of deaths related to chronic respiratory conditions 68 occur in low-and middle-income countries (LMICs), and the burden of disease is 69 expected to increase in many LMICs due to rapid urbanization and increased tobacco 70 consumption 2 .
72
Over the past decade, population-based, cross-sectional studies have examined 73 obstructive lung disease among LMICs 3-5 . Among these studies, a percentage of 74 participants were found to have restrictive spirometric values demonstrating reduced 75 forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) with 76 preserved overall FEV1/FVC ratio [6] [7] [8] . Although restriction in spirometry is not restrictive 77 lung disease, which typically requires measurement of total lung capacity and/or gas 78 transfer, studies in high-income settings have shown that restrictive spirometric patterns 79 (RSP) can result in higher risk of morbidity (respiratory symptoms and function status 80 limitation) as well as all-cause mortality among individuals who present with these 81 findings 8 .
83
Global estimates for RSP range from 2.3% in Santiago, Chile to 68% among women in 84 Mumbai, India, though this variability may be a result of different definitions for RSP and 85 reference populations 6, 7 . RSP has been most commonly associated with obesity, 86 tobacco exposure and female gender in these settings 3,6 . In addition, countries with a 87 high prevalence of biomass cooking fuel use and tuberculosis also had higher 88 prevalence of RSP, though potential associations between biomass, tuberculosis and 89 RSP have not been studied at a household level 4, 9 . We analysed data from approximately 3,000 adults aged ≥35 years enrolled in a 111 longitudinal population-based study with annual follow-up from 2010-2013. All subjects 112 were randomly selected using a single-stage random selection process and only one 113 participant per household was enrolled. In Puno, recruitment was stratified to include 114 500 participants each from the urban and rural settings. Inclusion criteria were age ≥35 115 years, a full-time resident in the specified setting, and capacity to understand procedures 116 and consent to the study. Exclusion criteria were pregnancy, physical disability that 117 prevented measurement of blood pressure or anthropometry, or active pulmonary We defined restrictive spirometric patterns as a pre-bronchodilator FVC below the 5 th 138 percentile (Z score ≤ -1.64) and a post-bronchodilator FEV1/FVC ratio above the 5 th 139 percentile (Z score ≥ -1.64) of a reference population 8 , and COPD as a post- We then built multivariable linear mixed effects models with a random intercept and 161 random slope by individual to analyse the effect of having RSP at baseline on 162 longitudinal decline in pre-bronchodilator FEV1 and FVC 13 . All models were adjusted for 163 sex, daily use of biomass fuels, daily tobacco smoking, living in an urban setting, and 164 living at high altitude. We then used the estimated subject-specific random slopes The overall prevalence of restriction was 4.6%, with a range of 2.8% (Lima) to 6.9% 183 (Tumbes) when using the GLI mixed ethnic reference population (Figure 1 ). Being 184 female was associated with higher odds of RSP (OR=2.09; 95% CI 1.42-2.11) ( Figure   185 2). Similarly, living in a rural area was associated with a higher odds of having RSP 186 (OR=2.19; 95% CI 1.43 to 3.39) as well as diabetes (OR = 1.93, 95% CI 1.10-3.39).
187
There was a moderate association of elevated hs-CRP (interquartile OR=1.05; 95% CI 188 1.00-1.10) and a diagnosis of RSP. Daily smoking, daily use of biomass fuels, site 189 (urbanization and high altitude), age, BMI, history of tuberculosis, hypertension, and 190 chronic bronchitis were not by themselves associated with having RSP. however, we found that participants with RSP had an accelerated pre-bronchodilator 213 FEV1 decline when baseline pre-bronchodilator FEV1 was taken into account 214 (1.15%/year vs. 1.06%/year, respectively; p=0.003) ( Table 3) . were associated with RSP, those exposed to smoking and biomass did not have an 224 increased risk for RSP. Adjusted for baseline FEV1, participants with RSP had a small Published data show wide variation in prevalence of RSP among LMICs. In BOLD, the 229 rates of RSP ranged from 4.2% to 48.7%, with higher rates of RSP found among LMIC 230 using fixed-percent predicted cut offs to diagnose RSP 6 . Our results were consistent 231 with the prevalence of other Latin American countries in PLATINO, which found rates of 232 RSP ranging from 2.3% to 7%, and used LLN cut-offs as we did 7 . While our results demonstrate a trend towards greater symptoms among those with RSP 240 compared to those with normal spirometry, there were no significant differences 241 between groups as seen with COPD.
243
In high-income settings, where obesity is most closely linked to RSP, there is evidence 244 that RSP may be linked to pro-inflammatory conditions independent of obesity 8,23,24 . We 
Estimated lung function decline as a percentage of baseline forced expiratory volume (%/yr)
1.06% (1.04%, 1.07%) 0.89% (0.88%, 0.90%) 1.15% (1.10%, 1.22%) 1.06% (1.01%, 1.12%) Figure 1: Prevalence of RSP by age category, stratified by sex. Figure 2 : Odds Ratio of having RSP for rural environment vs. urban, women vs. men, living at high altitude (3800m) vs. low altitude (sea level), diabetes vs. no diabetes, hs-CRP (75 th vs 25 th percentile), daily biomass exposure vs non-daily, and daily smoking vs non-daily, stratified by sex. Figure 3 : Prevalence of negative health outcomes and respiratory symptoms (missed work days because of respiratory problems in the last 12 months, hospitalization for respiratory problems in the last 12 months, dyspnea on exertion, ever wheeze, phlegm, and cough in last 12 months) between groups (RSP vs. Non-restricted, non-obstructed vs. COPD).
Figure 4:
Baseline pre-bronchodilator Z scores vs change in lung function as a percentage of baseline, stratified by FEV1 and FVC. Longitudinal models were adjusted for sex, biomass exposure, tobacco exposure, urbanization and altitude. Data was grouped by baseline Z-score (20 bins for FEV1 and 21 bins for FVC). The mean values for lung function decline (with error bars showing ± one standard deviation) were plotted in black, with the non-binned values plotted in grey.
